- Home
- RAND vs INKT Comparison
RAND vs INKT Comparison
Compare RAND & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- INKT
- Stock Information
- Founded
- RAND 1969
- INKT 2017
- Country
- RAND United States
- INKT United States
- Employees
- RAND N/A
- INKT N/A
- Industry
- RAND Finance: Consumer Services
- INKT Medicinal Chemicals and Botanical Products
- Sector
- RAND Finance
- INKT Health Care
- Exchange
- RAND Nasdaq
- INKT Nasdaq
- Market Cap
- RAND 54.4M
- INKT 48.7M
- IPO Year
- RAND N/A
- INKT 2021
- Fundamental
- Price
- RAND $15.21
- INKT $14.91
- Analyst Decision
- RAND
- INKT Buy
- Analyst Count
- RAND 0
- INKT 3
- Target Price
- RAND N/A
- INKT $37.50
- AVG Volume (30 Days)
- RAND 4.7K
- INKT 201.7K
- Earning Date
- RAND 08-04-2025
- INKT 08-14-2025
- Dividend Yield
- RAND 10.98%
- INKT N/A
- EPS Growth
- RAND N/A
- INKT N/A
- EPS
- RAND N/A
- INKT N/A
- Revenue
- RAND $7,966,118.00
- INKT N/A
- Revenue This Year
- RAND N/A
- INKT N/A
- Revenue Next Year
- RAND N/A
- INKT N/A
- P/E Ratio
- RAND N/A
- INKT N/A
- Revenue Growth
- RAND 1.16
- INKT N/A
- 52 Week Low
- RAND $13.82
- INKT $4.56
- 52 Week High
- RAND $31.89
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- RAND 32.85
- INKT 49.04
- Support Level
- RAND $13.82
- INKT $13.10
- Resistance Level
- RAND $17.05
- INKT $18.00
- Average True Range (ATR)
- RAND 0.93
- INKT 2.10
- MACD
- RAND -0.42
- INKT -0.26
- Stochastic Oscillator
- RAND 26.73
- INKT 44.28
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.